BIO DESIGN LABBIO DESIGN LABBeyond the limitations of conventional viral vectors
Conventional retroviral, lentiviral, and AAV platforms carry well-known limitations
Secondary malignancy risks from uncontrolled integration near oncogenic sites
Increased manufacturing costs due to low transduction efficiency and high viral dose requirements
Limited payload capacity of AAV vectors (~4.7 kb)
Reduced transduction efficiency in hard‑to‑transduce cells
Transient gene expression
Dramatically reduced genomic integration frequency
Re‑dosing capability
Suitability for gene editing applications
Therapeutic risk reduction
Sustained long‑term gene expression
Minimal integration near oncogenic sites
Optimized safety profile for CAR‑based therapies
Alignment with FDA safety considerations on secondary malignancies
Scalable production
Multifold enhancement in transduction efficiency
Significant reduction in Cost of Goods (COGS)
Efficient targeting of hard‑to‑transduce cells (NK cells, HSCs)
Expanded payload capacity
| Expression / Metric | NI | SI | HE | AAV | Conventional Lenti/Retro |
|---|---|---|---|---|---|
| Long-Term Expression | |||||
| Expression Profile | — | Long-Term | Long-Term | — | Long-Term |
| Safety | — | Higher† | High | Moderate | Low |
| Transduction Efficiency | — | High | Higher† | Moderate | Moderate |
| Transgene Expression | — | High | High | — | Moderate |
| Transient Expression | |||||
| Expression Profile | Transient | — | — | Transient | — |
| Re-dosing Potential | High | — | — | — | — |
| Transduction Efficiency | High | — | — | Moderate | — |
The components that can be combined into tailored solutions for unmet needs
Component optimization based on target specs
Molecular validation & plasmid construction
Pilot‑scale viral vector production
Functional QC & vector potency verification
Strategic partnerships to accelerate next-generation therapeutic development
End-to-end design and production of vectors tailored to partner objectives
Co-development of therapeutics using indication-specific vectors
Access to proprietary vector platforms for partner development programs
Let’s engineer the future of genetic medicine together